MYB and CD4+/CD56+ hematodermic neoplasm: Our study provides a strong molecular link and rationale for further investigations of the clinical use of venetoclax in MYB‐fusion‐driven BPCDN that has the potential to improve the outcome of pediatric BPDCN patients.